Fluidiconic Biotechnology Co., Ltd.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Fluidiconic Biotechnology develops tumor microenvironment chips and culture analysis platforms to support faster and more accurate anticancer drug development. Its TMoC series simulates molecular gradients from blood vessels to the tumor core, preserving tumor genetics and drug responses. Combined with the MedSelect platform and BioVision software, the system enables high-throughput dynamic culture, automated imaging, and visualized analysis, while the BioLab platform provides customized chip integration and ODM services for R&D teams.
The content above was translated by Ai
Founded Year
2025
Unified Business No.
28115622
Status
Active
Number of Employees
10
Total Paid-in
Capital
41,753,334 (NT$)
Location of Company
Taiwan
, Hsinchu City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Fluidiconic Biotechnology (NTHU spin-off) develops MedSelect™, a tumor-on-a-chip and automated drug-screening platform. Leveraging patented microfluidics and patient-derived samples, it shortens preclinical oncology cycles, reduces animal studies, and builds a transcriptomic database to power AI-assisted drug design — targeting global CRO and pharma partnerships.
The content above was translated by Ai
